Results 201 to 210 of about 31,287 (242)
A case of propylthiouracil induced antineutrophil cytoplasmic antibody associated vasculopathy
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nikhil Dwivedi +2 more
wiley +1 more source
Ocular mucous membrane pemphigoid: A retrospective study
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer +3 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs of Today, 2005
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab
Tanya, Doan, Elena, Massarotti
openaire +2 more sources
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab
Tanya, Doan, Elena, Massarotti
openaire +2 more sources
Zeitschrift für Rheumatologie, 2010
Rituximab as a monoclonal antibody against CD20 was approved for treatment of patients with rheumatoid arthritis (RA) with inadequate response to or contraindication for the use of a TNF blocker. This article focuses on current results from clinical trials at different developmental stages as well as from registry data in anti-TNF non-responders ...
E, Feist, T, Dörner
openaire +2 more sources
Rituximab as a monoclonal antibody against CD20 was approved for treatment of patients with rheumatoid arthritis (RA) with inadequate response to or contraindication for the use of a TNF blocker. This article focuses on current results from clinical trials at different developmental stages as well as from registry data in anti-TNF non-responders ...
E, Feist, T, Dörner
openaire +2 more sources
Drugs, 1999
Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days in patients with relapsed indolent lymphoma. Counts
S V, Onrust, H M, Lamb, J A, Balfour
openaire +2 more sources
Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days in patients with relapsed indolent lymphoma. Counts
S V, Onrust, H M, Lamb, J A, Balfour
openaire +2 more sources
Immunotherapy, 2017
Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies.
Hebert, Vivien, Joly, Pascal
openaire +2 more sources
Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies.
Hebert, Vivien, Joly, Pascal
openaire +2 more sources
BioDrugs, 2007
An important role for B cells in the immunopathogenesis of rheumatoid arthritis (RA) is recognized. Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody that transiently depletes CD20+ B cells. A single course of rituximab (two intravenous infusions of 1,000mg given two weeks apart) with a stable dose of methotrexate significantly ...
James E, Frampton, Lesley J, Scott
openaire +2 more sources
An important role for B cells in the immunopathogenesis of rheumatoid arthritis (RA) is recognized. Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody that transiently depletes CD20+ B cells. A single course of rituximab (two intravenous infusions of 1,000mg given two weeks apart) with a stable dose of methotrexate significantly ...
James E, Frampton, Lesley J, Scott
openaire +2 more sources
Rotten Rituximab: Rituximab Related ILD
B36. THE GOOD, THE BAD, AND THE UGLY: DRUG TOXICITY CASE REPORTS, 2023B.S.K.R. Sabbula, V. Mehta, J. Akella
openaire +1 more source